ZA201105505B - Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye - Google Patents

Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Info

Publication number
ZA201105505B
ZA201105505B ZA2011/05505A ZA201105505A ZA201105505B ZA 201105505 B ZA201105505 B ZA 201105505B ZA 2011/05505 A ZA2011/05505 A ZA 2011/05505A ZA 201105505 A ZA201105505 A ZA 201105505A ZA 201105505 B ZA201105505 B ZA 201105505B
Authority
ZA
South Africa
Prior art keywords
rtki
eye
delivery
compounds
pharmaceutical composition
Prior art date
Application number
ZA2011/05505A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Malay Ghosh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA201105505B publication Critical patent/ZA201105505B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/05505A 2009-03-03 2011-07-26 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye ZA201105505B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15692209P 2009-03-03 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
ZA201105505B true ZA201105505B (en) 2013-10-30

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05505A ZA201105505B (en) 2009-03-03 2011-07-26 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Country Status (12)

Country Link
US (2) US20100227905A1 (https=)
EP (1) EP2403335B1 (https=)
JP (1) JP5583146B2 (https=)
KR (2) KR20110130454A (https=)
CN (1) CN102340991B (https=)
AU (1) AU2010221369B2 (https=)
BR (1) BRPI1012302A2 (https=)
CA (1) CA2753690A1 (https=)
ES (1) ES2508290T3 (https=)
MX (1) MX2011008731A (https=)
WO (1) WO2010101992A1 (https=)
ZA (1) ZA201105505B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2013019640A1 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2804632B1 (en) 2012-01-19 2019-09-18 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2992021B1 (en) * 2013-04-30 2020-07-22 Intas Pharmaceuticals Limited Novel cloning, expression & purification method for the preparation of ranibizumab
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
PL4065131T3 (pl) * 2019-11-28 2024-12-16 Caprika Srl Kompozycja do zastosowania doodbytniczego w leczeniu zaparć

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
RU2108112C1 (ru) * 1993-04-16 1998-04-10 Вакамото Фармасьютикал Ко., Лтд. Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования
US6232343B1 (en) * 1996-05-07 2001-05-15 Toray Industries, Inc. Ophthalmic preparations
DK1638941T3 (da) * 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
JP2009521510A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
KR20100051811A (ko) * 2007-07-20 2010-05-18 알콘, 인코퍼레이티드 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제

Also Published As

Publication number Publication date
BRPI1012302A2 (pt) 2015-09-22
WO2010101992A1 (en) 2010-09-10
AU2010221369B2 (en) 2014-03-13
US20100227905A1 (en) 2010-09-09
CA2753690A1 (en) 2010-09-10
EP2403335A1 (en) 2012-01-11
EP2403335B1 (en) 2014-08-20
CN102340991A (zh) 2012-02-01
JP2012519694A (ja) 2012-08-30
EP2403335A4 (en) 2012-08-29
JP5583146B2 (ja) 2014-09-03
KR20160135372A (ko) 2016-11-25
AU2010221369A1 (en) 2011-08-25
CN102340991B (zh) 2014-02-26
MX2011008731A (es) 2011-09-29
KR20110130454A (ko) 2011-12-05
US20130137741A1 (en) 2013-05-30
ES2508290T3 (es) 2014-10-16

Similar Documents

Publication Publication Date Title
ZA201105505B (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
ZA201105506B (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
IL214572A (en) Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
IL240749A0 (en) Polycyclic lysophosphatidic acid receptor antagonists, pharmaceutical compositions thereof, and uses thereof for the treatment or prevention of diseases or conditions
ZA201201627B (en) Compounds as tyrosine kinase modulators
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
PT2379511E (pt) Análogos substituídos de dicetopiperazina para utilização como agentes de administração de fármacos
LT2373681T (lt) Albiglutido farmacinės kompozicijos
EP2281557A4 (en) PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
EP2461809A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
EP2381773A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
IL212122A0 (en) Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
IL214655A0 (en) Pyrazole derivatives used as ccr4 receptor antagonists
ZA201106703B (en) Use of pharmaceutical compositions containing mesembrenone
EP2298282A4 (en) COMBINING MEDICAMENTS HAVING DIFFERENT PHYSICAL PROPERTIES IN A SINGLE PHARMACEUTICAL FORM
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
EP2552447A4 (en) STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
ZA201107122B (en) Stable pharmaceutical compositions of diclofenac
AU2007356856A1 (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKI) compounds to the eye
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
IL209418A0 (en) Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumours
IL225209A0 (en) History of dihydrobenzoxathiazpine, their preparation, pharmaceutical preparations and use as ampa receptor modulators